CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Povidone-IodineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug779 Observation of behavior and COVID-19 infection will be conducted. Wiki 0.71
drug775 Normal saline Wiki 0.50

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.07
D045169 Severe Acute Respiratory Syndrome NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2

The SARS-CoV-2 coronavirus pandemic is responsible for more than 180,000 deaths worldwide and 20,000 deaths in France. To date, no treatment or vaccine has been successful. Povidone-iodine is an antiseptic suitable for use on the skin and mucosa with potent virucidal activity, particularly against coronaviruses. It is marketed for oro-nasopharyngeal decolonization. 24 patients with positive nasopharyngeal SARS-CoV-2 carriage will be randomized (1:1) in an experimental group (benefiting from povidone iodine decolonization) or a control group. Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days. Patients will be followed for 7 days to evaluate the efficacy and safety of povidone iodine decolonization.

NCT04371965 COVID-19 Drug: Povidone-Iodine

Primary Outcomes

Measure: Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7

Time: Day 7

Secondary Outcomes

Measure: Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage

Time: Day0, Day1, Day3, Day5 and Day7

Measure: Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal cell cultures

Time: Day0, Day1, Day3, Day5 and Day7

Measure: Thyroid tests at Day0 and Day7

Time: Day0 and Day7

Measure: Patient satisfaction at Day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort)

Time: Day7

Measure: Daily presence of clinical signs in favour of COVID-19, including respiratory distress using NYHA scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea

Time: Day0, Day1, Day3, Day5 and Day7

Measure: Need for ward or intensive care hospitalization

Time: Day0, Day1, Day3, Day5 and Day7

2 Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?

COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that is present in the nose and mouth. This also could mean that there is less virus available to pass on to others. We want to see if the use of nose rinses and mouth washes using Povidone-Iodine will reduce the the amount of virus in the nose and throat of people who have tested positive for COVID-19 disease and also reduce the spread of infection within their household.

NCT04393792 Coronavirus Infection Drug: Povidone-Iodine Drug: Normal saline
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: viral load as measured by real time polymerase chain reaction (PCR)

Measure: Change in viral load in the oral and nasopharyngeal cavity

Time: Day 0, 2, 3, 7, 14

Secondary Outcomes

Description: Visual analogue score 1-5 per symptom via a smartphone app

Measure: Symptom severity in primary participants and co-residents

Time: Days 0 to 14

No related HPO nodes (Using clinical trials)